Mounjaro 7.5mg: what changes at this dose and what to expect

Why does Mounjaro have a titration schedule at all?

Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) that regulate appetite and blood-sugar control, while also slowing how quickly the stomach empties. That last effect is largely responsible for the nausea and digestive discomfort many people notice in the first weeks. The titration schedule exists to let your body adjust to each strength before moving higher.

The 2.5mg starting dose is there purely to settle your system. By the time most people reach 7.5mg, the worst of that initial adaptation is usually behind them. Nausea, if it appeared at lower doses, tends to be less pronounced at 7.5mg for that reason, though everyone's response is individual. A quick way to track this for yourself: keep a brief note on your phone of any symptoms after each weekly injection, and share it at your next clinical review. Takes under a minute and gives your prescriber something concrete to work from.

The NHS medicines page for tirzepatide describes the general side-effect profile across the schedule; the specifics of your titration timing belong in a conversation with your prescriber.

What weight-loss effect can you realistically expect at 7.5mg?

Mounjaro's licensed strengths run from 2.5mg to 15mg. In the SURMOUNT-1 trial (which randomised 2,539 adults with obesity and ran for 72 weeks) participants on the 15mg maintenance dose saw average body-weight reductions of around 20–21%. The full SURMOUNT programme, spanning both obesity and diabetes trials, involved more than 10,000 participants across all doses.

What that means practically: 7.5mg is a transitional dose. Some people's prescribers keep them here if they are tolerating it well and losing weight steadily; others move through to 10mg or higher. NICE's appraisal of tirzepatide, TA1026, notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed. The key phrase there is 'highest tolerated', 7.5mg may not be that point yet for most people.

Appetite reduction is cumulative across the titration. Many people find that hunger patterns shift noticeably between 5mg and 7.5mg, though weight loss response varies considerably. For a closer look at how the previous dose compares, the 5mg dose page covers that step in detail.

Who is prescribed Mounjaro at this strength, and when?

Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. None of that eligibility picture changes at 7.5mg, the licence criteria are the same across all strengths.

What changes is your clinical picture. Before a prescriber moves you from 5mg to 7.5mg, they will want to know that you have tolerated the lower dose, and ideally that you are seeing some treatment response. At nume, every repeat order involves a clinical review by a GPhC-registered prescriber (not an automated check) before any dose change is confirmed. You can read more about how our clinical team approaches this on the clinical team page.

If you are currently on 5mg and wondering whether progression makes sense, the Mounjaro 5mg plateau page covers what to do if weight loss has stalled at the lower dose. For a broader picture of the full treatment, the Mounjaro overview is a good starting point. And if questions about cost are part of your thinking, our treatment and pricing page sets out what is included transparently.

What side effects are most common at this stage of treatment?

The side-effect profile at 7.5mg is consistent with the rest of the schedule: gastrointestinal effects are the most frequently reported, including nausea, loose stools, constipation, indigestion and reduced appetite. For many people these ease off between doses as the body adapts. Injection-site reactions, headache and fatigue are also reported, though less commonly.

One side effect that applies across the entire GLP-1 and dual-agonist class is worth knowing specifically: acute pancreatitis is an infrequent but potentially serious risk. Severe stomach pain that spreads to your back (with or without vomiting) needs prompt medical attention, not a wait-and-see approach. The MHRA highlighted this across GLP-1 medicines in a Drug Safety Update in January 2026.

If you experience anything unexpected, your prescriber is the first port of call. Suspected side effects can also be reported directly at the MHRA's Yellow Card scheme. Aftercare matters at every dose, at nume, prescriber support is available seven days a week. If you want to explore treatment under clinical supervision, you can speak to our prescribers as a starting point.